These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 27869048)

  • 1. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.
    Nomikos GG; Tomori D; Zhong W; Affinito J; Palo W
    CNS Spectr; 2017 Aug; 22(4):348-362. PubMed ID: 27869048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
    Baldwin DS; Florea I; Jacobsen PL; Zhong W; Nomikos GG
    J Affect Disord; 2016 Dec; 206():140-150. PubMed ID: 27474960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.
    Boulenger JP; Loft H; Olsen CK
    Int Clin Psychopharmacol; 2014 May; 29(3):138-49. PubMed ID: 24257717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
    Mahableshwarkar AR; Jacobsen PL; Chen Y; Serenko M; Trivedi MH
    Psychopharmacology (Berl); 2015 Jun; 232(12):2061-70. PubMed ID: 25575488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vortioxetine for depression in adults.
    Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
    Wang G; Gislum M; Filippov G; Montgomery S
    Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
    Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults.
    Thase ME; Mahableshwarkar AR; Dragheim M; Loft H; Vieta E
    Eur Neuropsychopharmacol; 2016 Jun; 26(6):979-93. PubMed ID: 27139079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vortioxetine: a New Treatment for Major Depressive Disorder.
    Connolly KR; Thase ME
    Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.
    Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Serretti A
    J Psychiatry Neurosci; 2015 May; 40(3):174-86. PubMed ID: 25350320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis.
    Fu J; Chen Y
    Psychopharmacology (Berl); 2015 Jan; 232(1):7-16. PubMed ID: 24871704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
    Llorca PM; Lançon C; Brignone M; Rive B; Salah S; Ereshefsky L; Francois C
    Curr Med Res Opin; 2014 Dec; 30(12):2589-606. PubMed ID: 25249164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder.
    Nishimura A; Aritomi Y; Sasai K; Kitagawa T; Mahableshwarkar AR
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):64-72. PubMed ID: 28858412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Serenko M; Chen Y; Trivedi MH
    J Clin Psychiatry; 2015 May; 76(5):583-91. PubMed ID: 26035186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
    Baldwin DS; Chrones L; Florea I; Nielsen R; Nomikos GG; Palo W; Reines E
    J Psychopharmacol; 2016 Mar; 30(3):242-52. PubMed ID: 26864543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine.
    Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Fornaro M; Fiengo ALC; Martinotti G; Vellante F; Matarazzo I; Vecchiotti R; Perna G; Di Nicola M; Carano A; Di Bartolomeis A; De Giannantonio M; De Berardis D
    CNS Neurol Disord Drug Targets; 2017; 16(1):65-92. PubMed ID: 27781949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
    Jacobsen PL; Mahableshwarkar AR; Serenko M; Chan S; Trivedi MH
    J Clin Psychiatry; 2015 May; 76(5):575-82. PubMed ID: 26035185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vortioxetine in the treatment of major depression].
    de Bartolomeis A; Fagiolini A; Maina G
    Riv Psichiatr; 2016; 51(6):215-230. PubMed ID: 27996982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G; Wang X; Ma D
    Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.